Please assess the completion status of the following clinical trial:

Trial Title: STOP-COVID19: Superiority Trial Of Protease Inhibition in COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~6.1. Inclusion criteria~• Male or female~* ≥16 years of age~* SARS-CoV-2 infection (clinically suspected+ or laboratory confirmed\*).~* Admitted to hospital as in-patient less than 96 hours prior to randomisation\^~* Illness of any duration, and at least one of the following:~  * Radiographic infiltrates by imaging (e.g. chest x-ray, computed tomography (CT) scan) OR~ * Evidence of rales/crackles on physical examination OR~ * Peripheral capillary oxygen saturation (SpO2) ≤94% on room air prior to randomization OR~ * Requiring supplemental oxygen. OR~ * Lymphocyte count \<1 x 109 cells per litre (L)~* Participant (or legally authorized representative) provides written informed consent~* Able to take oral medication~* Participant (or legally authorised representative) understands and agrees to comply with planned trial procedures.~  * Laboratory-confirmed: SARS-CoV-2 infection as determined by polymerase chain reaction (PCR), or other commercial or public health assay in any specimen \< 96 hours prior to randomization.~    * Clinically suspected: in general, SARS-CoV-2 infection should be suspected when a patient presents with (i) typical symptoms (e.g. influenza-like illness with fever and muscle pain, or respiratory illness with cough and shortness of breath); and (ii) compatible chest X-ray findings (consolidation or ground-glass shadowing); and (iii) alternative causes have been considered unlikely or excluded (e.g. heart failure, influenza). However, the diagnosis remains a clinical one based on the opinion of the managing doctor~      * Where a patient has been admitted to hospital for a non COVID-19 reason and develops COVID-19 symptoms whilst an in-patient, randomisation may occur up to 96 hours from onset of symptoms.~Exclusion Criteria:~* Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) \> 5 times the upper limit of normal, result within 72 hours of randomization (the result closest to randomization should be used if several results are available).~* History of severe liver disease~* Stage 4 severe chronic kidney disease or requiring dialysis (i.e. estimated Glomerular Filtration Rate \< 30), result within 72 hours of randomization (the result closest to randomization should be used if several results are available)~* Absolute neutrophil count less than 1.0 x 109 cells per L within 72 hours of randomization (the result closest to randomization should be used if several results are available)~* Current treatments with potent Cyp3A4 inducers/inhibitors (e.g Itraconazole, Ketoconazole, diltiazem, verapamil, phenytoin or rifampicin)~* HIV treatments - current treatment with protease/integrase inhibitors or non-nucleoside reverse transcriptase inhibitors\*~* Pregnant or breast feeding.~* Anticipated transfer to another hospital which is not a trial site within 24 hours.~* Allergy to Brensocatib~* Use of any investigational drug within five times of the elimination half-life after the last trial dose or within 30 days, whichever is longer. Co-enrolment with COVID-19 trials is allowed as per co-enrolment agreements and/or individual decision by the Chief Investigator.~Women of child-bearing potential must be willing to have pregnancy testing prior to trial entry.~\*The Liverpool HIV checker (https://www.hiv-druginteractions.org/checker) should be used to check for any HIV drug interactions. Simvastatin could be used as a surrogate for Brensocatib as it metabolised similarly by CYP 3A4 pathway.~-

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Brensocatib (Type: EXPERIMENTAL): Brensocatib oral tablet, 25mg once per day for 28 days
- Placebo (Type: PLACEBO_COMPARATOR): Placebo oral tablet, 25mg once per day for 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).